Health Catalyst, Inc. HCAT
- Market cap
- $131.0M
- P/E
- 0.0×
Follow HCAT
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | 26.00 | 17.48 | 35.96 | 6.40 | 6.60 | 5.42 | 2.02 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | 49.85 | 45.56 | 59.50 | 40.65 | 15.87 | 11.41 | 7.65 |
High Price
|
|||
| — | — | 728 | 900 | 1,000 | 1,200 | 1,200 | 1,300 | 1,500 | 1,200 |
Employees
|
|||
| — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | 73 | 113 | 155 | 189 | 242 | 276 | 296 | 307 | 311 |
Revenue
|
|||
| — | 40.28% | 46.83% | 51.37% | 48.06% | 48.60% | 48.21% | 44.55% | 45.92% | 48.75% |
Gross Margin
|
|||
| — | (47) | (62) | (60) | (116) | (160) | (142) | (118) | (69) | (177) |
EBT
|
|||
| — | (64.32%) | (55.18%) | (38.69%) | (61.54%) | (66.18%) | (51.29%) | (39.80%) | (22.56%) | (56.97%) |
EBT Margin
|
|||
| — | (47) | (62) | (60) | (115) | (153) | (137) | (118) | (70) | (178) |
Net Income
|
|||
| — | 6 | 8 | 10 | 27 | 49 | 50 | 44 | 45 | 164 |
Depreciation
|
|||
| — | 15.08 | 23.46 | 8.27 | 4.78 | 5.09 | 5.14 | 5.25 | 5.09 | 4.45 |
Revenue/Sh
|
|||
| — | (9.70) | (12.92) | (12.86) | (2.91) | (3.23) | (2.56) | (2.09) | (1.15) | (2.55) |
Earnings/Sh
|
|||
| — | (7.60) | (8.40) | (1.72) | (0.66) | (0.49) | (0.66) | (0.59) | 0.24 | 0.01 |
Cash Flow/Sh
|
|||
| — | (0.68) | (0.52) | (0.23) | (0.26) | (0.39) | (6.03) | (0.25) | (0.27) | (0.31) |
Capex/Sh
|
|||
| — | (8.28) | (8.91) | (1.95) | (0.93) | (0.88) | (6.69) | (0.84) | (0.03) | (0.30) |
Free CF/Sh
|
|||
| — | 0.00 | (78.11) | 10.71 | 6.98 | 10.99 | 7.91 | 6.50 | 6.07 | 3.52 |
Book Value/Sh
|
|||
| — | 5 | 5 | 19 | 40 | 47 | 54 | 56 | 60 | 70 |
Shares
|
|||
| — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | 0.00 | 0.00 | 4.20 | 9.11 | 7.78 | 2.02 | 1.74 | 1.39 | 0.54 |
PS Ratio
|
|||
| — | 0.00 | 0.00 | 3.24 | 6.23 | 3.60 | 1.31 | 1.40 | 1.17 | 0.68 |
PB Ratio
|
|||
| — | 0.00 | 0.00 | 3.05 | 8.59 | 6.70 | 1.54 | 1.45 | 1.36 | 0.72 |
EV/Sales
|
|||
| — | (3.30) | (3.30) | (12.98) | (44.32) | (39.00) | (1.18) | (9.04) | (227.75) | (10.81) |
EV/FCF
|
|||
| — | (37) | (40) | (32) | (26) | (23) | (35) | (33) | 15 | 1 |
Op' Cash Flow
|
|||
| — | (3) | (2) | (4) | (10) | (18) | (324) | (14) | (16) | (22) |
Capex
|
|||
| — | (40) | (43) | (36) | (37) | (42) | (359) | (47) | (2) | (21) |
FCF
|
|||
| — | 40 | 25 | 216 | 242 | 415 | 345 | 304 | 140 | 80 |
Working Cap'
|
|||
| — | 13 | 20 | 51 | 172 | 184 | 230 | 228 | 382 | 153 |
Total Debt
|
|||
| — | (39) | (13) | (177) | (99) | (261) | (134) | (90) | (10) | 58 |
Net Debt
|
|||
| — | 0 | (375) | 201 | 276 | 522 | 425 | 367 | 365 | 246 |
Sh' Equity
|
|||
| — | (53.14%) | (205.49%) | (116.57%) | (26.14%) | (21.73%) | (17.34%) | (16.25%) | (8.91%) | (26.14%) |
ROA
|
|||
| — | 0.00% | 0.00% | (146.71%) | (33.97%) | (34.34%) | (30.02%) | (28.61%) | (12.27%) | (33.15%) |
ROIC
|
|||
| — | 18.54% | 35.95% | 276.72% | (48.25%) | (38.39%) | (29.02%) | (29.84%) | (18.99%) | (58.26%) |
ROE
|
|||
Health Catalyst, Inc. (HCAT) key facts
- Health Catalyst, Inc. (HCAT) is a Health Information Services company in the Healthcare sector, listed on Nasdaq.
- Health Catalyst, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $311.1 million, up 1.48% from fiscal 2024.
- As of September 25, 2026, HCAT traded at $1.74, a market capitalization of $131.0 million.
- Return on equity was −58.3% and debt-to-equity 1.52.
Health Catalyst, Inc. (HCAT) Latest News
25 Sep
StockStory flags Health Catalyst (HCAT) as one of three unprofitable stocks to avoid, citing weak fundamentals and costly growth initiatives. HCAT carries a trailing GAAP operating margin of -84.4% and relies on its Health Catalyst Flywheel to drive measurable clinical, financial, and operational improvements in healthcare data analytics. The piece highlights a 14.4% slide in billings over the past year, a gross margin of 51.2% that trails peers, and customer-acquisition costs that take a while to recoup, complicating sales and marketing investments. At about $1.76 per share, HCAT trades near 0.6x forward price-to-sales. The article notes the lack of obvious near-term catalysts and suggests there are better opportunities elsewhere, pointing to profitability concerns as the primary risk. Portrays ongoing profitability issues and weak growth metrics, potentially dampening sentiment and short-term valuation for HCAT.
10 Sep
Health Catalyst appoints new CEO. New CEO appointment signals major strategic shift with potential to alter company trajectory and investor sentiment.
8 Sep
Health Catalyst appoints Simeon Kohl as Chief Executive Officer and President. CEO appointment may moderately affect strategic direction and market perception.
13 Aug
Health Catalyst (HCAT) released its Q2 2026 earnings call transcript covering quarterly financial results, performance metrics, and forward-looking guidance. Earnings transcripts disclose financial results and guidance that typically drive material shifts in valuation and investor positioning.
11 Aug
Health Catalyst divested Vitalware, reshaping strategy amid Q2 revenue decline. Vitalware divestiture marks major strategic shift alongside revenue decline that will likely alter company trajectory.
7 Aug
Health Catalyst, Inc. held its Q2 2026 earnings call covering quarterly financial results, operational updates, and forward guidance for its healthcare analytics platform. Quarterly earnings updates typically affect near-term stock sentiment and valuation but rarely shift long-term competitive positioning.
6 Aug
Health Catalyst exceeded Q2 CY2026 expectations but its stock dropped 25.5%. Stock fell 25.5% after the earnings beat pointing to major investor concerns over future outlook.
Health Catalyst Q2 earnings call covered financial results, operational updates, and outlook for the healthcare data analytics company. Quarterly earnings updates typically influence near-term sentiment and guidance without fundamentally shifting long-term trajectory.
Health Catalyst completed the sale of Vitalware to sharpen its focus exclusively as a healthcare intelligence company. Sale of Vitalware enables Health Catalyst to redirect resources and strategy toward core healthcare intelligence operations.
Health Catalyst, Inc. reported its second quarter 2026 financial results. Quarterly earnings updates deliver financial metrics that may shift short-term market views without altering long-term trajectory.
4 Jun
Health Catalyst agrees to sell Vitalware for $147 million to speed up strategic transformation. Divestiture of Vitalware for $147 million constitutes a major strategic move that alters Health Catalyst's business focus and financial outlook.
Med-Metrix enters definitive agreement to acquire Vitalware to enhance coding accuracy and net revenue yield. Vitalware acquisition by Med-Metrix may alter Health Catalyst portfolio and revenue streams.
19 May
Health Catalyst's Q1 earnings call highlighted five key analyst questions on financial results, growth strategies and operational priorities. Q1 earnings call analyst questions deliver moderate insights into strategy and outlook that can influence near-term investor sentiment.
13 May
Health Catalyst (HCAT) Q1 earnings report imminent, with focus on revenue expectations, subscription growth, ARR metrics, margins, profitability, and forward guidance amid analyst forecasts. Q1 earnings outcomes likely to moderately affect financial results and investor sentiment without fundamentally altering long-term trajectory.
12 May
Health Catalyst Inc (HCAT) Q1 2026 earnings call highlights surpassing expectations with strong financial performance. Surpassing Q1 2026 earnings expectations indicates robust financial results likely to enhance investor confidence and stock trajectory.
11 May
Health Catalyst released Q1 earnings call highlights, detailing financial results, revenue growth, operational updates, and forward guidance amid healthcare analytics market dynamics. Q1 earnings highlights disclose key financial metrics, strategic initiatives, and guidance that significantly influence investor sentiment and stock trajectory.
Health Catalyst (HCAT) released Q1 2026 earnings call transcript detailing quarterly financial results, operational updates, and forward guidance. Q1 2026 earnings transcript discloses key financial metrics, revenue growth, and strategic initiatives significantly shaping HCAT's future performance and investor outlook.
Health Catalyst (HCAT) Q1 earnings and revenues surpassed analyst estimates. Q1 earnings and revenue beats demonstrate strong financial performance, likely driving positive investor sentiment and stock price gains.
Health Catalyst’s Q1 CY2026 sales beat estimates, driving an 11.1% stock jump. Q1 sales beat estimates and triggered 11.1% stock surge, significantly boosting investor sentiment and short-term performance.
Health Catalyst, Inc. (HCAT) reported first quarter 2026 results. Quarterly earnings directly affect financial performance, guidance, and investor sentiment.
Health Catalyst (HCAT) Q1 earnings key metrics compared to analyst estimates, highlighting performance against expectations. Q1 earnings metrics directly influence financial performance and short-term market sentiment.
10 May
Health Catalyst (HCAT) investment narrative shifts amid AI developments, leadership changes, and execution risks. Leadership changes and execution risks represent major strategic shifts that could significantly impact HCAT's trajectory and market performance.
30 Apr
Health Catalyst, Inc. (HCAT) appoints Steve Nelson, President of Aetna, to its Board of Directors to leverage his extensive healthcare leadership experience. Appointing Aetna's president strengthens Health Catalyst's board with deep payer expertise and potential for strategic partnerships.
27 Mar
Analysts are resetting expectations for Health Catalyst (HCAT), shifting its investment story amid evolving dynamics in healthcare data analytics. Analysts resetting expectations represents a significant shift in market sentiment and HCAT's valuation trajectory.
20 Mar
Wells Fargo downgraded Health Catalyst (HCAT) to Equal Weight from Overweight, citing prolonged revenue growth slowdown and margin pressures amid softer healthcare IT spending and contract delays. Analyst downgrade signals significant investor sentiment shift due to persistent revenue and margin challenges.
17 Mar
Health Catalyst (HCAT) released its Q4 2025 earnings call transcript, detailing financial results, operational highlights, strategic initiatives, and forward-looking guidance. Q4 earnings transcripts disclose key financial metrics, revenue growth, profitability updates, and future outlook that drive substantial shifts in market performance and investor confidence.
Health Catalyst's Q4 results highlight margin expansion efforts and ongoing strategic review amid challenges from platform migration pressures. Margin focus and strategic review counterbalanced by platform migration pressures point to moderately noticeable effects on financial performance and investor sentiment.
13 Mar
Health Catalyst, Inc. Q4 2025 earnings call summary highlights financial results, operational updates, and forward guidance for the healthcare analytics firm. Q4 earnings call summaries disclose key financials and strategic outlook that significantly sway stock performance and investor expectations.
12 Mar
Health Catalyst Q4 earnings call highlights financial results, operational achievements, strategic updates, and forward-looking guidance. Q4 earnings call highlights provide key financial metrics and guidance that significantly shape investor expectations and stock trajectory.
Health Catalyst Inc (HCAT) Q4 2025 earnings call highlights revenue challenges while detailing navigation strategies and key financial updates. Revenue challenges disclosed in Q4 2025 earnings call will moderately impact HCAT's financial trajectory and investor sentiment.